OG Acquisition 2 Corp. acquires Concenter BioPharma

OG Acquisition 2 Corp. agreed to acquire Concenter BioPharma. Reported deal value: $1.6M. Status: Pending. Sector: Biotechnology. Target headquarters context: Israel.

This page summarizes publicly available information about the transaction as of 2026-01-12. Figures and status may change as filings and press coverage update.

OG Acquisition 2 Corp . today announced a significant milestone in its previously disclosed letter of intent with Concenter BioPharma , as Concenter advances preparations for its second clinical trial using its oral dose drug focused on addressing the underlying the root cause of Type 2 Diabetes, the worlds’ silent killer”